U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C7H9NO6S
Molecular Weight 235.214
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of POMAGLUMETAD

SMILES

[H][C@@]12[C@@H](C(O)=O)[C@]1([H])S(=O)(=O)C[C@@]2(N)C(O)=O

InChI

InChIKey=AVDUGNCTZRCAHH-MDASVERJSA-N
InChI=1S/C7H9NO6S/c8-7(6(11)12)1-15(13,14)4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12)/t2-,3-,4+,7+/m1/s1

HIDE SMILES / InChI

Molecular Formula C7H9NO6S
Molecular Weight 235.214
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

LY404039 [(-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid] is an agonist of orthosteric metabotropic glutamate receptor (mGluR)2/3. In addition, it acts as an agonist at dopamine D2 receptors. LY404039 demonstrated broad antipsychotic and anxiolytic efficacy across multiple animal models. LY-2140023 is a methionine amide prodrug of LY-404039 being developed by Eli Lilly & Co for the potential oral treatment of schizophrenia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
149.0 nM [Ki]
92.0 nM [Ki]
80.0 nM [EC50]
Conditions
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
2007 Apr
Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.
2007 Jan 25
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.
2013 Aug
A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia.
2014 Dec 10
Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).
2015 Jan
Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects.
2018 Jul
Successes, failures, and future prospects of prodrugs and their clinical impact.
2019 Mar
Patents

Sample Use Guides

Phase 3 study for the treatment of schizophrenia: 40 mg LY2140023 (prodrug of LY404039) administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time. Mice: 3-30 mg/kg i.p.
Route of Administration: Oral
rat primary astrocytes were treated with 100 uM LY404039
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:12:09 UTC 2023
Edited
by admin
on Fri Dec 15 18:12:09 UTC 2023
Record UNII
531QUG7P9E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
POMAGLUMETAD
Common Name English
LY-404039, (-)-
Code English
2-THIABICYCLO(3.1.0)HEXANE-4,6-DICARBOXYLIC ACID, 4-AMINO-, 2,2-DIOXIDE, (1R,4S,5S,6S)-
Common Name English
LY-404039
Code English
LY404039
Code English
Code System Code Type Description
WIKIPEDIA
Pomaglumetad
Created by admin on Fri Dec 15 18:12:10 UTC 2023 , Edited by admin on Fri Dec 15 18:12:10 UTC 2023
PRIMARY
PUBCHEM
9834591
Created by admin on Fri Dec 15 18:12:10 UTC 2023 , Edited by admin on Fri Dec 15 18:12:10 UTC 2023
PRIMARY
EPA CompTox
DTXSID40212943
Created by admin on Fri Dec 15 18:12:10 UTC 2023 , Edited by admin on Fri Dec 15 18:12:10 UTC 2023
PRIMARY
FDA UNII
531QUG7P9E
Created by admin on Fri Dec 15 18:12:10 UTC 2023 , Edited by admin on Fri Dec 15 18:12:10 UTC 2023
PRIMARY
CAS
635318-11-5
Created by admin on Fri Dec 15 18:12:10 UTC 2023 , Edited by admin on Fri Dec 15 18:12:10 UTC 2023
PRIMARY
CHEBI
94640
Created by admin on Fri Dec 15 18:12:10 UTC 2023 , Edited by admin on Fri Dec 15 18:12:10 UTC 2023
PRIMARY
ChEMBL
CHEMBL375611
Created by admin on Fri Dec 15 18:12:10 UTC 2023 , Edited by admin on Fri Dec 15 18:12:10 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Ki
TARGET -> AGONIST
Ki
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY